cmAngio® vs AI-ECG Tracker

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CureMetrix
VS
by Carewell Health

AI Verdict

Tool A, cmAngio®, focuses on detecting Breast Arterial Calcifications on mammograms to assess cardiovascular risk, primarily for women's health. In contrast, Tool B, AI-ECG Tracker, specializes in AI-powered auto-diagnosis of cardiac abnormalities directly from ECG data. While both contribute to cardiovascular health, their distinct data inputs and diagnostic approaches make them adjacent rather than direct competitors.

Choose cmAngio® if…

Choose cmAngio® if your clinical goal is to leverage existing mammography data for proactive cardiovascular risk assessment in women. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to provide early insights into a patient's cardiovascular health without requiring additional radiation or procedures.

View cmAngio® →

Choose AI-ECG Tracker if…

Choose AI-ECG Tracker if you require rapid and highly accurate AI-powered auto-analysis and diagnosis of cardiac abnormalities from 12-lead ECGs. This solution is particularly well-suited for cardiology and emergency medicine settings where quick identification of conditions like arrhythmias, myocardial ischemia, or infarction is critical for timely patient management.

View AI-ECG Tracker →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature cmAngio® AI-ECG Tracker
Pricing Paid, out-of-pocket Unknown
Deployment Cloud-based, integrates with any DICOM-compliant viewer Mobile app, intended for use by qualified healthcare professionals in hospitals and other healthcare facilities.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

cmAngio®

Tool A emphasizes quick and easy installation (less than an hour) and seamless compatibility with any DICOM-compliant viewer, suggesting minimal disruption to existing workflows. Its cloud-based deployment generally offers easier management compared to Tool B's on-premise workstation with optional cloud.

Clinical Value

AI-ECG Tracker

Tool B offers high accuracy (over 95%, with some sources citing 98.3%) for a broad range of critical cardiac abnormalities, including arrhythmias and myocardial infarction, with rapid analysis in approximately 3 seconds. While Tool A provides innovative cardiovascular risk assessment from mammograms, Tool B's direct diagnostic utility for a wider array of acute cardiac conditions gives it a slight edge in immediate clinical impact.

Pricing & Value

cmAngio®

Both tools lack publicly available pricing details. However, Tool A explicitly mentions 'limited-time offers for no-cost implementation and service' for the first three months, providing a tangible, albeit temporary, value proposition that Tool B does not.

Enterprise Readiness

cmAngio®

Tool A demonstrates stronger enterprise readiness with explicit statements of HIPAA compliance and cybersecurity, cloud-native deployment, and expanded FDA clearance for major mammography platforms (Hologic, GE). Its MDSAP certification also indicates broader international market readiness.

Innovation

cmAngio®

Tool A is highly innovative by being the first and currently only FDA-cleared AI software to detect Breast Arterial Calcifications (BAC) on mammograms, repurposing existing imaging data for cardiovascular risk assessment. This effectively creates a 'two-for-one' exam, leveraging current screening practices for a new, significant clinical insight.

Support & Docs

Tie

Neither tool provides extensive public details regarding their support channels or comprehensive documentation. While Tool A mentions an 'Operator's Manual' and Tool B refers to customizable reports, there isn't enough specific information to definitively distinguish between them in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature cmAngio® AI-ECG Tracker
Tool Name cmAngiou00ae AI-ECG Tracker
Company CureMetrix Shenzhen Carewell Electronics Co.
Primary Function AI software for detecting Breast Arterial Calcifications (BAC) on mammograms AI technology for ECG auto-diagnosis
Key Feature 1 AI-based detection of Breast Arterial Calcifications (BAC) AI-powered ECG auto-analysis and diagnosis
Key Feature 2 Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams High accuracy (over 95%) for common cardiac abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction
Specialties Cardiology, Obstetrics & Gynecology, Radiology Cardiology, Emergency Medicine

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and AI-ECG Tracker.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

cmAngiou00ae detects Breast Arterial Calcifications (BAC) on mammograms, offering insights into cardiovascular health and aiding early risk assessment. AI-ECG Tracker provides AI-powered auto-analysis and diagnosis of 12-lead ECG data for common cardiac abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction.
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. AI-ECG Tracker supports 12-lead ECG data collection.
cmAngiou00ae is relevant for Cardiology, Obstetrics & Gynecology, and Radiology. AI-ECG Tracker is designed for Cardiology and Emergency Medicine.
cmAngiou00ae enables BAC identification and reporting without additional radiation or procedures and offers quick and easy installation (less than an hour). AI-ECG Tracker provides rapid diagnosis in approximately 3 seconds with high accuracy (over 95%) for common cardiac abnormalities.

Backers

Who funded each tool's parent company.

cmAngio®

AI Tool Finder
AI-powered search. Results may not be comprehensive.